Stifel analyst Scott Devitt upgrades Netflix (NASDAQ:NFLX) from Hold to Buy and raises the price target from $240 to $250.
Freeline Therapeutics Announces Second Round Of Layoffs, Shelves Fabry Disease Program
Freeline Therapeutics Holdings plc (NASDAQ:FRLN) further assessed its strategic priorities and decided to pause the development of FLT190 in Fabry disease…